Personalized Medicine in Severe Asthma: From Biomarkers to Biologics
International Journal of Molecular Sciences · 22.12.2023 · 25 (1) · 182
DOI: 10.3390/ijms25010182 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.12.2023. Verfasst von Chun-Yu Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Tungs' Taichung Metro Harbor Hospital, Taichung 435403, Taiwan. Hauptthemen laut MEDLINE: Biological Products, Asthma, Blood Group Antigens. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe asthma is a complex and heterogeneous clinical condition presented as chronic inflammation of the airways. Conventional treatments are mainly focused on symptom control; however, there has been a shift towards personalized medicine. Identification of different phenotypes driven by complex pathobiological mechanisms (endotypes), especially those driven by type-2 (T2) inflammation, has led to improved treatment outcomes. Combining biomarkers with T2-targeting monoclonal antibodies is crucial for developing personalized treatment strategies. Several biological agents, including anti-immunoglobulin E, anti-interleukin-5, and anti-thymic stromal lymphopoietin/interleukin-4, have been approved for the treatment of severe asthma. These biological therapies have demonstrated efficacy in reducing asthma exacerbations, lowering eosinophil count, improving lung function, diminishing oral corticosteroid use, and improving the quality of life in selected patients. Severe asthma management is undergoing a profound transformation with the introduction of ongoing and future biological therapies. The availability of novel treatment options has facilitated the adoption of phenotype/endotype-specific approaches and disappearance of generic interventions. The transition towards precision medicine plays a crucial role in meticulously addressing the individual traits of asthma pathobiology. An era of tailored strategies has emerged, allowing for the successful targeting of immune-inflammatory responses that underlie uncontrolled T2-high asthma. These personalized approaches hold great promise for improving the overall efficacy and outcomes in the management of severe asthma. This article comprehensively reviews currently available biological agents and biomarkers for treating severe asthma. With the expanding repertoire of therapeutic options, it is becoming increasingly crucial to comprehend the influencing factors, understand the pathogenesis, and track treatment progress in severe asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, Tungs' Taichung Metro Harbor Hospital, Taichung 435403, Taiwan.
- Department of Nursing, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 35664, Taiwan.
- Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
- Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan.
- Division of Pediatric Emergency Medicine, Department of Pediatrics, Taichung Veteran General Hospital, Taichung 43503, Taiwan.
ORCID-Profile: Kang-Hsi Wu, Bei-Cyuan Guo, Yu-Jun Chang, Han-Ping Wu
Zitieren
APA
Chen, C. Y., Wu, K. H., Guo, B. C., Lin, W. Y., Chang, Y. J., Wei, C. W., Lin, M. J., & Wu, H. P. (2023). Personalized Medicine in Severe Asthma: From Biomarkers to Biologics. International Journal of Molecular Sciences, 25(1), 182. https://doi.org/10.3390/ijms25010182
Vancouver
Chen CY, Wu KH, Guo BC, Lin WY, Chang YJ, Wei CW, et al. Personalized Medicine in Severe Asthma: From Biomarkers to Biologics. International Journal of Molecular Sciences. 2023;25(1):182. doi:10.3390/ijms25010182
BibTeX
@article{Chen2023,
author = {Chen, Chun-Yu and Wu, Kang-Hsi and Guo, Bei-Cyuan and Lin, Wen-Ya and Chang, Yu-Jun and Wei, Chih-Wei and Lin, Mao-Jen and Wu, Han-Ping},
title = {Personalized Medicine in Severe Asthma: From Biomarkers to Biologics},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {25},
number = {1},
pages = {182},
doi = {10.3390/ijms25010182}
}
EUVIMED